{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle&page=12",
    "query": {
      "intervention": "Vehicle",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 1695,
    "total_pages": 170,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T08:09:32.653Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02634853",
      "title": "A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "1% Tavilermide Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mimetogen Pharmaceuticals USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 429,
      "start_date": "2015-12",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2019-08-16",
      "last_synced_at": "2026-10-18T08:09:32.653Z",
      "location_count": 2,
      "location_summary": "Louisville, Kentucky • Nashville, Tennessee",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02634853"
    },
    {
      "nct_id": "NCT04893486",
      "title": "CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BCCs in Gorlin Syndrome Patients"
      ],
      "interventions": [
        {
          "name": "PTX-022",
          "type": "DRUG"
        },
        {
          "name": "Vehicle comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Palvella Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2021-05-06",
      "completion_date": "2023-03-13",
      "has_results": false,
      "last_update_posted_date": "2024-08-29",
      "last_synced_at": "2026-10-18T08:09:32.653Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Hot Springs, Arkansas • Palo Alto, California + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Orange Park",
          "state": "Florida"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04893486"
    },
    {
      "nct_id": "NCT02793817",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Post Surgical Ocular Inflammation and Pain"
      ],
      "interventions": [
        {
          "name": "KPI-121 1% Ophthalmic Suspension dosed BID",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of KPI-121 Ophthalmic Suspension dosed BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kala Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 520,
      "start_date": "2016-06",
      "completion_date": "2017-03",
      "has_results": true,
      "last_update_posted_date": "2020-12-16",
      "last_synced_at": "2026-10-18T08:09:32.653Z",
      "location_count": 35,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Artesia, California + 32 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02793817"
    },
    {
      "nct_id": "NCT05759208",
      "title": "The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OK-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Okyo Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2023-04-28",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2024-02-09",
      "last_synced_at": "2026-10-18T08:09:32.653Z",
      "location_count": 6,
      "location_summary": "Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05759208"
    },
    {
      "nct_id": "NCT05635838",
      "title": "Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2022-12-07",
      "completion_date": "2024-03-14",
      "has_results": true,
      "last_update_posted_date": "2024-11-01",
      "last_synced_at": "2026-10-18T08:09:32.653Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05635838"
    },
    {
      "nct_id": "NCT05688735",
      "title": "Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Isosorbide Diester Moisturizer",
          "type": "OTHER"
        },
        {
          "name": "Control Moisturizer",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Integrative Skin Science and Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 40,
      "start_date": "2023-04-20",
      "completion_date": "2024-03-31",
      "has_results": false,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-10-18T08:09:32.653Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05688735"
    },
    {
      "nct_id": "NCT04286789",
      "title": "Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Low dose ORTD-1",
          "type": "DRUG"
        },
        {
          "name": "Low dose vehicle control",
          "type": "DRUG"
        },
        {
          "name": "High dose ORTD-1",
          "type": "DRUG"
        },
        {
          "name": "High dose vehicle control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oryn Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2021-03-22",
      "completion_date": "2021-10-12",
      "has_results": false,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-10-18T08:09:32.653Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Tustin, California • Miami, Florida",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04286789"
    },
    {
      "nct_id": "NCT03761784",
      "title": "A Study of S6G5T-3 in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "S6G5T-3",
          "type": "DRUG"
        },
        {
          "name": "S6G5T-8",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sol-Gel Technologies, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 424,
      "start_date": "2018-12-21",
      "completion_date": "2019-12-31",
      "has_results": true,
      "last_update_posted_date": "2021-12-16",
      "last_synced_at": "2026-10-18T08:09:32.653Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03761784"
    },
    {
      "nct_id": "NCT01010633",
      "title": "Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Inflammation",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Vehicle of Loteprednol Etabonate",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol Etabonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 406,
      "start_date": "2009-11",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2012-01-09",
      "last_synced_at": "2026-10-18T08:09:32.653Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01010633"
    },
    {
      "nct_id": "NCT03547206",
      "title": "Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonarteritic Anterior Ischemic Optic Neuropathy"
      ],
      "interventions": [
        {
          "name": "RPh201 Cohort A",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cohort A",
          "type": "OTHER"
        },
        {
          "name": "RPh201 Cohort B",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cohort B",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regenera Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2018-07-10",
      "completion_date": "2020-09-27",
      "has_results": false,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-10-18T08:09:32.653Z",
      "location_count": 15,
      "location_summary": "Palo Alto, California • Pasadena, California • Orange, Connecticut + 12 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "Connecticut"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03547206"
    }
  ]
}